Paper39796647
New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.
Liu L and 2 others. Cancers (Basel), 2024. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective. Papers, record 39796647. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796647
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References58
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35842959 | Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP. | Comput Biol Chem | 2022 | https://conductscience.org/library/papers/35842959 | PubMed |
| 2 | 27237051 | Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. | Mol Cell | 2016 | https://conductscience.org/library/papers/27237051 | PubMed |
| 3 | 19800812 | Variation in breast cancer subtypes with age and race/ethnicity. | Crit Rev Oncol Hematol | 2010 | https://conductscience.org/library/papers/19800812 | PubMed |
| 4 | 30911337 | HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. | Ther Adv Med Oncol | 2019 | https://conductscience.org/library/papers/30911337 | PubMed |
| 5 | 26627007 | Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. | Cancer Res | 2015 | https://conductscience.org/library/papers/26627007 | PubMed |
| 6 | 26673665 | Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. | Cell Death Dis | 2015 | https://conductscience.org/library/papers/26673665 | PubMed |
| 7 | 31752925 | Distinct functions of AKT isoforms in breast cancer: a comprehensive review. | Cell Commun Signal | 2019 | https://conductscience.org/library/papers/31752925 | PubMed |
| 8 | 26759240 | Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. | Cancer Res | 2016 | https://conductscience.org/library/papers/26759240 | PubMed |
| 9 | 39476340 | Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39476340 | PubMed |
| 10 | 31474751 | A new era of long-read sequencing for cancer genomics. | J Hum Genet | 2020 | https://conductscience.org/library/papers/31474751 | PubMed |
| 11 | 16847462 | The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. | Nat Rev Genet | 2006 | https://conductscience.org/library/papers/16847462 | PubMed |
| 12 | 16168105 | Somatic mutation and gain of copy number of PIK3CA in human breast cancer. | Breast Cancer Res | 2005 | https://conductscience.org/library/papers/16168105 | PubMed |
| 13 | 24587488 | Classes of phosphoinositide 3-kinases at a glance. | J Cell Sci | 2014 | https://conductscience.org/library/papers/24587488 | PubMed |
| 14 | 31928690 | Efficacy of PI3K inhibitors in advanced breast cancer. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31928690 | PubMed |
| 15 | 25533673 | PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. | Nat Rev Cancer | 2015 | https://conductscience.org/library/papers/25533673 | PubMed |
| 16 | 20569503 | Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. | Breast Cancer Res | 2010 | https://conductscience.org/library/papers/20569503 | PubMed |
| 17 | 25284480 | Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25284480 | PubMed |
| 18 | 31091374 | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31091374 | PubMed |
| 19 | 32175074 | mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. | Cell Biosci | 2020 | https://conductscience.org/library/papers/32175074 | PubMed |
| 20 | 16724053 | Ras, PI(3)K and mTOR signalling controls tumour cell growth. | Nature | 2006 | https://conductscience.org/library/papers/16724053 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42668644 | A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice. | Mar Life Sci Technol | 2026 | https://conductscience.org/library/papers/42668644 | PubMed |
| 42477186 | Identification of miR-21-5p and miR-21-3p regulated hub genes and drug repurposing targets in cervical cancer: an integrative computational analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/42477186 | PubMed |
| 42296160 | Unlocking precision diagnostics: A multimodal framework integrating metabolomics with advanced machine learning techniques. | PLoS One | 2026 | https://conductscience.org/library/papers/42296160 | PubMed |
| 42113367 | Long non-coding RNAs as modulators of endocrine therapy response in hormone receptor-positive breast cancer. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42113367 | PubMed |
| 42041716 | Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42041716 | PubMed |
| 41976378 | Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41976378 | PubMed |
| 41764610 | Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview. | Mini Rev Med Chem | 2026 | https://conductscience.org/library/papers/41764610 | PubMed |
| 41514656 | Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514656 | PubMed |
| 41512289 | Postpartum breast cancer: evidence for a distinct phenotype. | J Natl Cancer Inst | 2026 | https://conductscience.org/library/papers/41512289 | PubMed |
| 41233438 | Proteomics characterization of triple-negative apocrine carcinoma reveals molecular features of progression and chemotherapy response. | Sci Rep | 2025 | https://conductscience.org/library/papers/41233438 | PubMed |
| 41182651 | SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025). | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41182651 | PubMed |
| 41157256 | Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review. | Life (Basel) | 2025 | https://conductscience.org/library/papers/41157256 | PubMed |
| 40924238 | Targeting the tumor microenvironment in colorectal cancer: the effect of Rapamycin on angiogenesis, apoptosis, and STAT5A/TORC1 signaling. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40924238 | PubMed |
| 40868155 | Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review. | Biomedicines | 2025 | https://conductscience.org/library/papers/40868155 | PubMed |
| 40725184 | The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725184 | PubMed |
| 40676293 | PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40676293 | PubMed |
| 40421216 | CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40421216 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796647
GET https://conductscience.org/api/papers/v1/39796647/references?page=2